DocGo Inc. 8-K

What Happened

• DocGo Inc. (DCGO) filed an 8-K (Item 3.01) reporting that on January 26, 2026 Nasdaq’s Listing Qualifications staff notified the company it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below the $1.00 minimum from December 9, 2025 through January 23, 2026. The notice does not have immediate delisting effect and the Company’s Nasdaq listing remains active.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) — $1.00 minimum bid requirement.
• Deficiency period observed: closing bids from December 9, 2025 to January 23, 2026.
• Compliance deadline: 180 days from the notice — until July 27, 2026; to regain compliance the stock must close at or above $1.00 for at least ten consecutive business days before that date.
• If not cured, DocGo may be eligible for a second 180-day cure period only if it meets other initial listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure; a reverse stock split is one potential remedy the company says it will consider.

Why It Matters

• For investors, this is a material listing-risk disclosure: failure to regain compliance could lead to delisting from the Nasdaq Capital Market, which can reduce liquidity and make shares harder to trade. The notice itself does not change the company’s listing today, but it creates a clear deadline and potential pressure on management to act (for example, via a reverse stock split) to restore the share price. DocGo says it will monitor the bid price and evaluate options to regain compliance.